VeriSign (VRSN) continues to make notable strides in the biotech market; indications are rife with recent major shifts in stock activities. Many asset management firms like Cambridge Investment Research Advisors, Janney Montgomery Scott, Achmea Investment Management and Mirae Asset Global Investments have increased their stakes in Verisign substantially. On the flip side, certain entities like Appleton Partners, Canoe Financial and Assenagon Asset Management have reduced their stock positions. Insider trading activities indicate, top Verisign executives sold hundreds of shares, CEO D. James Bidzos liquidated around 9,000 shares. An analyst from Baird raised the price target of Verisign to $305.
Impressively, the stock hit a new 52-week high. Q4 earnings show a strong outperformance compared to the rest of e-commerce software stocks. So far, the financial results have been on par with expectations, with consistent earnings and domain base expansions contributing to a rise in guidance. Despite the hustle, the Q1 2025 results are highly anticipated by investors.
Regarding the Board, Verisign announced the resignation of long-standing board member, Thomas Frist.
Therefore, the bullish momentum on Verisign stock seems to be just starting, with continued support from investment giants like Berkshire Hathaway and Renaissance Technologies.
Verisign VRSN News Analytics from Thu, 26 Dec 2024 08:00:00 GMT to Sat, 05 Jul 2025 07:26:40 GMT - Rating 8 - Innovation 7 - Information 6 - Rumor 4
